ArticlePLoS neglected tropical diseases2018
A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.
Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.Nature communications · 2024Trial
- Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection.PLoS neglected tropical diseases · 2026Review
- Diversity of Chagas disease diagnostic antigens: Successes and limitations.PLoS neglected tropical diseases · 2024Review
- IgG Isotypes Targeting a Recombinant Chimeric Protein of Trypanosoma cruzi in Different Clinical Presentations of Chronic Chagas Disease.The American journal of tropical medicine and hygiene · 2024Article
- Assessment of Cross-Reactivity of ChimericDiagnostics (Basel, Switzerland) · 2023Article
- Chagas disease treatment efficacy markers: experiences from a Phase III study with nifurtimox in children.Frontiers in parasitology · 2023Article
- Predictors of Trypanosoma cruzi PCR positivity in patients with chronic Chagas disease.Memorias do Instituto Oswaldo Cruz · 2023Observational
- Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure.PLoS neglected tropical diseases · 2022Article
- Temporal and Wash-Out Studies Identify Medicines for Malaria Venture Pathogen Box Compounds with Fast-Acting Activity against BothMicroorganisms · 2022Article
- A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.PLoS neglected tropical diseases · 2021Article
- Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.Parasites & vectors · 2021Article
- A refined genome phage display methodology delineates the human antibody response in patients with Chagas disease.iScience · 2021Article
- Cohort profile update: the main and new findings from the SaMi-Trop Chagas cohort.Revista do Instituto de Medicina Tropical de Sao Paulo · 2021Article
- Declining antibody levels to Trypanosoma cruzi correlate with polymerase chain reaction positivity and electrocardiographic changes in a retrospective cohort of untreated Brazilian blood donors.PLoS neglected tropical diseases · 2020Article
- Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.PLoS neglected tropical diseases · 2020Article
- Assessment of multiplex Onchocerca volvulus peptide ELISA in non-endemic tropical regions.Parasites & vectors · 2019Article
- TcTASV Antigens ofThe American journal of tropical medicine and hygiene · 2019Article
- A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.Antimicrobial agents and chemotherapy · 2019Article
- Performance evaluation of 3 serodiagnostic peptide epitopes and the derived multi-epitope peptide OvNMP-48 for detection of Onchocerca volvulus infection.Parasitology research · 2019Article
- Pathology and Pathogenesis of Chagas Heart Disease.Annual review of pathology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundTrypanosoma cruzi parasite, the causative agent of Chagas disease, infects about six million individuals in more than 20 countries. Monitoring parasite persistence in infected individuals is of utmost importance to develop and evaluate treatments to control the disease. Routine screening for infected human individuals is achieved by serological assays; PCR testing to monitor spontaneous or therapy-induced parasitological cure has limitations due to the low and fluctuating parasitic load in circulating blood. The aim of the present study is to evaluate a newly developed antibody profiling assay as an indirect method to assess parasite persistence based on waning of antibodies following spontaneous or therapy-induced clearance of the infection. METHODOLOGY/PRINCIPAL
findingsWe designed a multiplex serology assay, an array of fifteen optimized T. cruzi antigens, to evaluate antibody diversity in 1654 serum samples from chronic Chagas patients. One specific antibody response (antibody 3, Ab3) showed a strong correlation with T. cruzi parasite persistence as determined by T. cruzi PCR positive results. High and sustained Ab3 signal was strongly associated with PCR positivity in untreated patients, whereas significant decline in Ab3 signals was observed in BZN-treated patients who cleared parasitemia based on blood PCR results. CONCLUSION/SIGNIFICANCE: Ab3 is a new surrogate biomarker that strongly correlates with parasite persistence in chronic and benznidazole-treated Chagas patients. We hypothesize that Ab3 is induced and maintained by incessant stimulation of the immune system by tissue-based and shed parasites that are not consistently detectable by blood based PCR techniques. Hence, a simple immunoassay measurement of Ab3 could be beneficial for monitoring the infectious status of seropositive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.